Dipyrone-related granulocytopenia. Case report

  • Jorge Enrique Machado-Alba a. Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira. b. Audifarma S.A. Pereira, Colombia.
  • Leidy Viviana Sánchez-Morales Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira.
  • Luisa Fernanda Rodríguez-Ramírez a. Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira. b. Audifarma S.A. Pereira, Colombia.
Keywords: Dipyrone, Agranulocytosis, Pharmacovigilance, Adverse effects, Case Report

Abstract

Introduction:

Dipyrone has been positioned in several countries as one of the first over-the-counter options for pain management. Its possible adverse effects are known worldwide; among them, agranulocytosis is the most lethal, with a mortality of approximately 10% and an associated risk of 1 per 1,000,000 patients.

Clinical findings, interventions, and outcomes:

A case of a patient who, after 23 days of using dipyrone for pain management, developed a progressive drop in leukocyte count. Other potential causes of the event were ruled out. After dipyrone discontinuation, leukocyte counts returned to their normal values.

Conclusion:

The probable diagnosis of granulocytopenia as a dipyrone-related adverse drug reaction was established. Although rare, dipyrone-related granulocytopenia, may occur in patients who use this medication for long periods.

References

1. Buitrago-González TP, Calderón-Ospina CA, Vallejos-Narváez Á. Dipyrone: Benefits underestimated or oversized risks? Review of the literature. Rev Colomb Cienc Quím Farm 2014;43:173-195.

2. Derry S, Faura C, Edwards J, et al. Single dose dipyrone for acute postoperative pain. Cochrane Database Syst Rev 2010;9:CD003227.

3. Koster HT, Avis HJ, Stevens MF, et al. Metamizole in postoperative pain management. Ned Tijdschr Geneeskd 2012;156:A4323.

4. Montoya GA, Vaca C, Parra MF. Adverse events associated with tramadol and dipirona administration in a level III hospital. Biomédica 2009;29:369-381.

5. Salgado P, Suarez-de-la-Rica A, Maseda E, et al. Severe Mucor necrotizing fasciitis associated to dipyrone-induced agranulocytosis. Rev Esp Quimioter 2015;28:58-60.

6. Basak GW, Drozd-Sokolowska J, Wiktor-Jedrzejczak W. Update on the incidence of metamizole sodium-induced blood dyscrasias in Poland. J Int Med Res 2010;38:1374-1380.

7. Arbeláez-Quintero I, Jiménez-Cardozo N. Agranulocytosis risk during use of Dipyrone: a systematic literature review. Salutem Scientia Spiritus 2015;1:19-24.

8. Hamerschlak N, Cavalcanti AB. Neutropenia, agranulocytosis and dipyrone. Sao Paulo Med J 2005;123:247-249.

9. Iskra MP, Membrilla E, Isbert F, et al. Severe sepsis due to cervical abscess after agranulocytosis associated with metamizole. Cir Esp 2015;93:e83-e85.

10. Dorr VJ, Cook J. Agranulocytosis and near fatal sepsis due to ‘Mexican aspirin’ (dipyrone). South Med J 1996;89:612-614.

11. Blaser LS, Tramonti A, Egger P, et al. Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports. Eur J Clin Pharmacol 2015;71:209-217.

12. AronsonJK. Metamizole (dipyrone) A2 - Meyler’s Side Effects of Drugs. 16th ed. Oxford: Elsevier; 2016; 859-862.

13. Kose N, Akin. PP-216 a case of inferior acute myocardial infarction due to intravenous metamizole use. Int J Cardiol 2013;163 (3 suppl 1):S166.

14. Garcipérez de Vargas FJ, Mendoza J, Sánchez-Calderón P, et al. Cardiogenic shock secondary to metamizole-induced type II Kounis syndrome. Rev Esp Cardiol 2012;65:1138-1139.

15. Redondo-Pachon MD, Enriquez R, Sirvent AE, et al. Acute renal failure and severe thrombocytopenia associated with metamizole. Saudi J Kidney Dis Transpl 2014;25:121-125.

16. Machado-Alba JE, Urbano-Garzón SF, Gallo-Gómez YN, Zuluaica S, Henao Y, Parrado-Fajardo IY. Reacción de anafilaxia grave por dipirona sin antecedente de hipersensibilidad. Informe de caso. Rev Colomb Anestesiol 2017;45:8-11.

17. Stamer UM, Soehle M, Park T-W, et al. Anaphylactic reaction after intravenous dipyrone. Acute Pain 2007;9:221-227.

18. Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 2002;58:265-274.

19. Ip J, Uetrecht JP. In vitro and animal models of drug-induced blood dyscrasias. Environ Toxicol Pharmacol 2006;21:135-140.

20. Uetrecht JP, Ma HM, MacKnight E, et al. Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis. Chem Res Toxicol 1995;8:226-233.

21. Hargis JB, La Russa VF, Redmond J, et al. Agranulocytosis associated with “Mexican aspirin” (dipyrone): evidence for an autoimmune mechanism affecting multipotential hematopoietic progenitors. Am J Hematol 1989;31:213-215.

22. Ibáñez L, Vidal X, Ballarín E, et al. Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 2005;60:821-829.

23. Busto U, Naranjo CA, Sellers EM. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. Br J Clin Pharmacol 1982;13:223-227.
How to Cite
1.
Machado-Alba JE, Sánchez-Morales LV, Rodríguez-Ramírez LF. Dipyrone-related granulocytopenia. Case report. Colomb. J. Anesthesiol. [Internet]. 2018Oct.1 [cited 2021Jan.26];46(4):327 -330. Available from: https://www.revcolanest.com.co/index.php/rca/article/view/409

Downloads

Download data is not yet available.
Published
2018-10-01
How to Cite
1.
Machado-Alba JE, Sánchez-Morales LV, Rodríguez-Ramírez LF. Dipyrone-related granulocytopenia. Case report. Colomb. J. Anesthesiol. [Internet]. 2018Oct.1 [cited 2021Jan.26];46(4):327 -330. Available from: https://www.revcolanest.com.co/index.php/rca/article/view/409
Section
Case Report / Case Series

More on this topic